Market Overview

Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy

Related SNY
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
European advisory group backs Sanofi's fexinidazole for sleeping sickness (Seeking Alpha)

Argus' Stephen Biggar initiated coverage of Sanofi SA (ADR) (NYSE: SNY) with a Buy rating and $50 price target as the company has moved past a challenging period.

According to Biggar, Sanofi has suffered through a period in which two of its best selling drugs, Lantus (diabetes) and Plavix (prevention of blood clots) have seen their patents expire. The company also had to deal with legal issues, including a court ruling in which its cholesterol-lowering therapy Praluent infringed on patents held by rival pharmaceutical firm Amgen, Inc. (NASDAQ: AMGN).

Amgen 'Largely Moved Past' Prior Headwinds

Biggar now believes Amgen has "largely moved past" these events and investors can look forward to the company benefiting from the strong demand for its multiple sclerosis drugs and management's cost-cutting initiatives.

Biggar added that Amgen also boasts a strong pipeline of new drugs, including Toujeo, which is a next-generation insulin product. Other notable therapies in the pipeline include dipilumab for atopic dermatitis and other inflammatory conditions.

Valuation Is Attractive

Biggar further noted that Sanofi's stock is trading at 15.4x his 2017 earnings per ADS forecast which is short of the average multiple of 16.2x for S&P 500 Pharma companies. The analyst believes the stock shouldn't trade at a discount to the group average, rather it should trade at a slight premium given the company's positioning for growth.

Sanofi also pays investors a sustainable dividend which has been raised over the past 23 years and currently yields around 3.5 percent.

See also:

Argus Initiates Bioverativ With Hold

Here Are The 4 Commercial Launches In 2017 That Earned Tesaro A Buy Rating At Argus

Latest Ratings for SNY

Nov 2018ArgusMaintainsBuyBuy
Nov 2018BarclaysUpgradesUnderweightEqual-Weight
Sep 2018Bank of AmericaUpgradesNeutralBuy

View More Analyst Ratings for SNY
View the Latest Analyst Ratings

Posted-In: Argus Lantus Patents PharmaceuticalAnalyst Color Price Target Initiation Analyst Ratings


Related Articles (AMGN + SNY)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mid-Day Market Update: Crude Oil Up Over 1%; Synacor Shares Plunge

7-Eleven's $3.3 Billion Expansion In The U.S.